Nasus Pharma Ltd. (NSRX) — Cash Flow-to-Debt Ratio
Nasus Pharma Ltd. (NSRX) has a Cash Flow-to-Debt Ratio of -2.20x as of December 2025, meaning its operating cash flow of $-4.92 Million could theoretically repay -2% of its total liabilities ($2.24 Million) in one year. See Nasus Pharma Ltd. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nasus Pharma Ltd. Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Nasus Pharma Ltd. across 4 annual periods. Also explore Nasus Pharma Ltd. annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nasus Pharma Ltd. (2022–2025)
Year-by-year debt coverage analysis for Nasus Pharma Ltd.. For market capitalisation and broader financial context, see Nasus Pharma Ltd. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-4.92 Million | $2.24 Million | ▼ -1199.5% |
| 2024 | -0.17x | $-665.00K | $3.93 Million | ▲ +30.2% |
| 2023 | -0.24x | $-1.03 Million | $4.24 Million | ▲ +35.8% |
| 2022 | -0.38x | $-1.21 Million | $3.20 Million | — |